论文部分内容阅读
目的探讨艾滋病(AIDS)高效抗逆转录病毒治疗(HAART)的疗效及副作用。方法对14例应用HAART(拉米夫定、司他夫定、奈伟拉平)的AIDS病人进行回顾性分析,并评价药物的不良反应。结果CD4+T细胞<50个/μl的7例AIDS病人中,1例疗效较好,6例短期内死亡;而CD4+T细胞>50个/μl的7例AIDS病人中,6例较好,1例在短期内死亡。7例持续治疗的病人,CD4+T细胞治疗前与治疗后比较差异有统计学意义(P<0.05)。结论HAART对多数AIDS病人效果显著,然病情较重者,多难以见到疗效,因此需严格掌握HAART时机。另外,本组免费药物显示出良好的耐受性,是多数病人的一个重要选择。
Objective To investigate the efficacy and side effects of HAART. Methods A retrospective analysis was performed on 14 AIDS patients with HAART (lamivudine, stavudine, and nevirapine), and the adverse drug reactions were evaluated. Results Of the 7 AIDS patients with CD4 + T cells <50 cells / μl, 1 was better and 6 cases died within a short period of time. Of the 7 AIDS patients with CD4 + T cells> 50 cells / μl, 6 were better , One case died in a short period of time. Seven patients with continuous treatment, CD4 + T cells before and after treatment, the difference was statistically significant (P <0.05). Conclusions HAART is effective in most AIDS patients. However, when the condition is severe, HAART can hardly see the curative effect. Therefore, it is necessary to strictly grasp the HAART timing. In addition, free drugs in this group show good tolerability and are an important choice for most patients.